Dr Tobias Menne
University of Birmingham
Cancer Research UK, AstraZeneca & Imagine for Margo
Acute Lymphoblastic Leukaemia (ALL)
Clinical Trial Of an Investigational Medicinal Product
Recruitment Start Date:
Anticipated Recruitment End Date:
CRCTU Trial Management Team:
Early Drug Development Team
This trial is to investigate the combination of selumetinib and dexamethasone in the treatment of relapsed/refractory acute lymphoblastic leukaemia (ALL) in both adults and children. The trial is specifically for patients who have an identified change (mutation) in a particular gene in their cancer’s DNA. Phase I is to find the most suitable dose of selumetinib to safely give with dexamethasone. Phase II will use this dose to find out how well the combination works.
Please note that the trials team cannot give individuals clinical advice. Patients who are interested in taking part in the trial and their families are advised to contact their health care professional to discuss if they may be eligible or refer to the CancerHelp website (see link below under More Information).
For Participating Sites
Please visit the For Investigators page which allow hospital sites participating in the SeluDex trial to access information and download current study documentation (password protected).